Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that it confirmed an appeal filed by the Seoul Central District Prosecutors’ Office to the Supreme Court regarding the second-instance acquittal ruling on alleged accounting rule violations. The issues under appeal remain identical to the indictment filed on September 4, 2020. 📊…

Read More “[Disclosure] Samsung Biologics (207940) – Measures Such as Prosecution Notice for Breach of Accounting Standards / 2025-02-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is issuing 41,475 additional common shares through the exercise of stock options, scheduled to be listed on February 13, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Share Count Adjustment Following Additional Listing This disclosure…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Exercise of Stock Options) / 2025-02-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion published a corrected disclosure finalizing its dividend yield (0.4%) and eligible share count (205,030,873 shares) as of the record date (December 31, 2024). The cash dividend is set at KRW 750 per common share, totaling approximately KRW 153.77B. 📊 Key Disclosure Content & Financial Highlights…

Read More “[Disclosure] Celltrion (068270) – (Correction) Decision on Cash & In-Kind Dividend / 2025-02-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion published a corrected disclosure clarifying the explanatory text regarding its stock dividend of 0.05 common shares per share (total 10,251,543 shares), following the finalization of eligible shares as of the record date (December 31, 2024). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment…

Read More “[Disclosure] Celltrion (068270) – (Correction) Stock Dividend Decision / 2025-02-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen decided on a third-party allotment paid-in capital increase issuing Redeemable Convertible Preferred Shares (RCPS) worth KRW 155.00B to fund plant construction, headquarters relocation, and operating expenses. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Full Capital Payment…

Read More “[Disclosure] ALTEOGEN (196170) – Decision on Paid-in Capital Increase (Third-Party Allotment – Redeemable Convertible Preferred Shares) / 2025-02-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure following receipt of the written second-instance court judgment, amending the description of alleged violations from “No violations” to “Appeal dismissed (Not guilty)” and removing the note regarding pending judgment receipt. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Results of Measures Such as Prosecution Notice for Breach of Accounting Standards / 2025-02-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that it received a “Not guilty” verdict in the second-instance court ruling (Seoul High Court) regarding alleged accounting rule violations. The company plans to issue a correction disclosure upon receipt of the written judgment. 📊 [Key Disclosure Details & Financial Figures] 📝…

Read More “[Disclosure] Samsung Biologics (207940) – Results of Measures Such as Prosecution Notice for Breach of Accounting Standards / 2025-02-03” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the US Food and Drug Administration (FDA) for Avtozma (CT-P47), an Actemra biosimilar, for key indications including rheumatoid arthritis across the United States. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of US…

Read More “[Disclosure] Celltrion (068270) – Approval of US FDA Marketing Authorization for Avtozma (CT-P47, Actemra Biosimilar) / 2025-01-31” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its FY2024 preliminary consolidated financial results, reporting revenue of KRW 4.547T (+23.1% YoY) and operating profit of KRW 1.320T (+18.5% YoY). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Revenue Changes and Upcoming Audit Report…

Read More “[Disclosure] Samsung Biologics (207940) – Change of 15% or More in Revenue or Profit/Loss Structure (Large-Scale Company) / 2025-01-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its provisional Q4 and FY2024 consolidated financial results via fair disclosure, reporting Q4 revenue of KRW 1.256T (+17.04% YoY) and operating profit of KRW 325.7B (-6.94% YoY). Full-year 2024 cumulative revenue reached KRW 4.547T (+23.08% YoY) with operating profit of KRW 1.320T…

Read More “[Disclosure] Samsung Biologics (207940) – Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure) / 2025-01-22” »